ARWR - Arrowhead Pharmaceuticals, Inc. News

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript

marketbeat.com

Arrowhead Pharmaceuticals Q3 Earnings Call Highlights

Arrowhead Pharmaceuticals NASDAQ: ARWR reported positive Phase III results for plozasiran in severe

Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analy

Arrowhead Pharmaceuticals Enters Agreement With Undisclosed Third Party To Acquire An FDA Rare Pedia

SNDA to seek approval to expand the approved indication to include patients with severe hypertriglyc

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

defenseworld.net

California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceut

California State Teachers Retirement System raised its stake in Arrowhead Pharmaceuticals, Inc. (NAS

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

B. Riley Securities Maintains Buy on Arrowhead Pharma, Raises Price Target to $123

B. Riley Securities analyst Madison El-Saadi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy

4 Health Care Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

gurufocus.com

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the

[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced that it has completed en

Ford To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst

Arrowhead Pharmaceuticals Completes Patient Enrollment In Its Global Phase 3 YOSEMITE Clinical Study

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in t

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with

defenseworld.net

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: A

defenseworld.net

California Public Employees Retirement System Makes New Investment in Arrowhead Pharmaceuticals, Inc

California Public Employees Retirement System purchased a new position in shares of Arrowhead Pharma

Morgan Stanley Maintains Overweight on Arrowhead Pharma, Raises Price Target to $120

Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and

Piper Sandler Reiterates Overweight on Arrowhead Pharma, Raises Price Target to $126

Piper Sandler analyst Edward Tenthoff reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight

Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) stock is trading higher on Wednesday as the company rev

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat

The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreati

Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential

Arrowhead Pharmaceuticals surged nearly 20% after strong Phase 3 results for plozasiran in severe hy

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday&#39

Stock Market Today: Nasdaq 100 Falls as Crude Rallies to $88

Stocks split as oil climbs on the 11th night of Iran strikes and Super Micro rockets 26% on a record

Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than

Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials

Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglycer

CME Group, Weatherford International, RPM International And Other Big Stocks Moving Higher On Wednes

Dow Jones up 200 pts, CME Group shares rise on upbeat earnings. Super Micro Computer, Arrowhead Phar

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers InMed Pharmaceuticals (NASDAQ:INM) stock moved upwards by 66.8% to $2.57 during Wednesday&#

gurufocus.com

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Ploz

[url="]Arrowhead Pharmaceuticals, Inc.[/url] (NASDAQ: ARWR) today announced topline results for the

Arrowhead Pharmaceuticals Announces Topline Results For Phase 3 SHASTA-3 And SHASTA-4 Clinical Studi

Statistically significant reduction in acute pancreatitis events versus placebo across the entire sH

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Ploz

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

finbold.com

These major drug stocks rally after Trump's zero tariff announcement

President Donald Trump has announced that all generic drugs imported into the United States would co

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today an

JP Morgan Maintains Overweight on Arrowhead Pharma, Raises Price Target to $95

JP Morgan analyst Brian Cheng maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and rais

This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

This Arrowhead Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations

Analysts changed outlook on top names, including RXO, AMBQ, BE, ARWR, FSLR. See ratings page for upg

Stifel Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $98

Stifel analyst James Condulis initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rat

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $100 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) wit

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development P

Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

247wallst.com

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending

Arrowhead Pharmaceuticals Receives European Commission Marketing Authorization For REDEMPLO To Lower

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the European Commission (EC) has

Leerink Partners Maintains Market Perform on Arrowhead Pharma, Raises Price Target to $72

Leerink Partners analyst Mani Foroohar maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Per

Arrowhead Presents Interim Results From Phase 1/2a Clinical Trial Of ARO-INHBE, Investigational RNAi

- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associate

Bernstein Maintains Market Perform on Arrowhead Pharma, Raises Price Target to $46

Bernstein analyst William Pickering maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Perfor

RBC Capital Maintains Outperform on Arrowhead Pharma, Raises Price Target to $87

RBC Capital analyst Luca Issi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and rais

Arrowhead Pharma Q2 EPS $(0.93) Beats $(1.14) Estimate, Sales $73.737M Miss $79.991M Estimate

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(0.93) per share which beat the analyst